{"cells":[{"cell_type":"code","source":["dbutils.fs.ls(\"/FileStore/tables/\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2357fce6-83ed-4ffb-879c-fd71ee6d6b8a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[43]: [FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1645025994000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019/', name='clinicaltrial_2019/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1648298404000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1648298480000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1648298499000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv_gz.gz', name='clinicaltrial_2021_csv_gz.gz', size=11921810, modificationTime=1651935392000),\n FileInfo(path='dbfs:/FileStore/tables/data_scrubbing_using_rdds.ipynb', name='data_scrubbing_using_rdds.ipynb', size=16994, modificationTime=1645531555000),\n FileInfo(path='dbfs:/FileStore/tables/devicestatus.zip', name='devicestatus.zip', size=23873574, modificationTime=1645532011000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations.zip', name='json_activations.zip', size=8411369, modificationTime=1645007727000),\n FileInfo(path='dbfs:/FileStore/tables/letter_frequencies.txt', name='letter_frequencies.txt', size=2593894, modificationTime=1646061760000),\n FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1645611185000),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1647965556000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1647965511000),\n FileInfo(path='dbfs:/FileStore/tables/spark_sql.ipynb', name='spark_sql.ipynb', size=10821, modificationTime=1646234376000),\n FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1646216350000)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[43]: [FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1645025994000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019/', name='clinicaltrial_2019/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1648298404000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1648298480000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1648298499000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv_gz.gz', name='clinicaltrial_2021_csv_gz.gz', size=11921810, modificationTime=1651935392000),\n FileInfo(path='dbfs:/FileStore/tables/data_scrubbing_using_rdds.ipynb', name='data_scrubbing_using_rdds.ipynb', size=16994, modificationTime=1645531555000),\n FileInfo(path='dbfs:/FileStore/tables/devicestatus.zip', name='devicestatus.zip', size=23873574, modificationTime=1645532011000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations.zip', name='json_activations.zip', size=8411369, modificationTime=1645007727000),\n FileInfo(path='dbfs:/FileStore/tables/letter_frequencies.txt', name='letter_frequencies.txt', size=2593894, modificationTime=1646061760000),\n FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1645611185000),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1647965556000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1647965511000),\n FileInfo(path='dbfs:/FileStore/tables/spark_sql.ipynb', name='spark_sql.ipynb', size=10821, modificationTime=1646234376000),\n FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1646216350000)]"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 1"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"0bfca0e8-fadf-4ae4-95b5-cff475bfe0c8"}}},{"cell_type":"code","source":["clinical_DF = spark.read.options( delimiter = '|', header= True).csv(\"/FileStore/tables/clinicaltrial_2021.csv\")\nclinical_DF.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4cbc95a4-bcdb-4bd6-a1a6-5ed5c7a5fb0a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|Appendicitis,Stom...|                null|\n|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|Hookworm Infectio...|                null|\n|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|             Ascites|                null|\n|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|Chronic Pain,Subs...|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|Appendicitis,Stom...|                null|\n|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|Hookworm Infectio...|                null|\n|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|             Ascites|                null|\n|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|Chronic Pain,Subs...|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["clinical_DF.distinct().count()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e147f4e0-fe37-458d-9bbb-523652691c6a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[45]: 387261","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[45]: 387261"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 2"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d2cab373-cbff-4df1-bc27-4a5754d8807c"}}},{"cell_type":"code","source":["Types = clinical_DF.filter(\"Type != ''\").groupby(\"Type\").count( ).orderBy(\"count\", ascending = False) \nTypes.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5bf0cdd6-65ab-442f-af66-d10c445a626a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|      Interventional|301472|\n|       Observational| 77540|\n|Observational [Pa...|  8180|\n|     Expanded Access|    69|\n+--------------------+------+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|      Interventional|301472|\n|       Observational| 77540|\n|Observational [Pa...|  8180|\n|     Expanded Access|    69|\n+--------------------+------+\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 3"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c98fbd5d-61e8-4d26-ac86-884864735b2c"}}},{"cell_type":"code","source":["from pyspark.sql.functions import *"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e8549ac1-9826-42fe-82f4-dc8bbf22fd4a"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["Conditions_1 = clinical_DF.select(explode(split(col(\"Conditions\"), \",\")).alias(\"Conditions\")).na.drop()\nConditions_1.show(10, truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3e94a6b7-f912-433a-8376-41fd8c984e08"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+------------------------+\n|Conditions              |\n+------------------------+\n|Autistic Disorder       |\n|Autism Spectrum Disorder|\n|Diabetes Mellitus       |\n|Tuberculosis            |\n|Lung Diseases           |\n|Pulmonary Disease       |\n|Diverticular Diseases   |\n|Diverticulum            |\n|Diverticulosis          |\n|Asthma                  |\n+------------------------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+------------------------+\n|Conditions              |\n+------------------------+\n|Autistic Disorder       |\n|Autism Spectrum Disorder|\n|Diabetes Mellitus       |\n|Tuberculosis            |\n|Lung Diseases           |\n|Pulmonary Disease       |\n|Diverticular Diseases   |\n|Diverticulum            |\n|Diverticulosis          |\n|Asthma                  |\n+------------------------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["Conditions = Conditions_1.groupBy(\"Conditions\").count().orderBy('count', ascending= False)\nConditions.show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d4b2dc85-f28e-47dd-8385-e6f63837f4cc"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------------+-----+\n|       Conditions|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------------+-----+\n|       Conditions|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 4"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"35c7383c-a1f0-492d-b458-08d1b40ee3ea"}}},{"cell_type":"code","source":["Mesh_DataFrame = spark.read.options( delimiter = ',', header= True).csv(\"/FileStore/tables/mesh.csv\")\nMesh_DataFrame.show(10, truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"24d380f5-3a28-4981-93d6-9e1a30049482"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------+-------------------+\n|term      |tree               |\n+----------+-------------------+\n|Calcimycin|D03.633.100.221.173|\n|A-23187   |D03.633.100.221.173|\n|Temefos   |D02.705.400.625.800|\n|Temefos   |D02.705.539.345.800|\n|Temefos   |D02.886.300.692.800|\n|Abate     |D02.705.400.625.800|\n|Abate     |D02.705.539.345.800|\n|Abate     |D02.886.300.692.800|\n|Difos     |D02.705.400.625.800|\n|Difos     |D02.705.539.345.800|\n+----------+-------------------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------+-------------------+\n|term      |tree               |\n+----------+-------------------+\n|Calcimycin|D03.633.100.221.173|\n|A-23187   |D03.633.100.221.173|\n|Temefos   |D02.705.400.625.800|\n|Temefos   |D02.705.539.345.800|\n|Temefos   |D02.886.300.692.800|\n|Abate     |D02.705.400.625.800|\n|Abate     |D02.705.539.345.800|\n|Abate     |D02.886.300.692.800|\n|Difos     |D02.705.400.625.800|\n|Difos     |D02.705.539.345.800|\n+----------+-------------------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["tree = Mesh_DataFrame.withColumn(\"tree\", substring(\"tree\", 0,3))\ntree.show(10, truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"70890e1e-a3ac-4578-b2b2-ef05c969ca90"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------+----+\n|term      |tree|\n+----------+----+\n|Calcimycin|D03 |\n|A-23187   |D03 |\n|Temefos   |D02 |\n|Temefos   |D02 |\n|Temefos   |D02 |\n|Abate     |D02 |\n|Abate     |D02 |\n|Abate     |D02 |\n|Difos     |D02 |\n|Difos     |D02 |\n+----------+----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------+----+\n|term      |tree|\n+----------+----+\n|Calcimycin|D03 |\n|A-23187   |D03 |\n|Temefos   |D02 |\n|Temefos   |D02 |\n|Temefos   |D02 |\n|Abate     |D02 |\n|Abate     |D02 |\n|Abate     |D02 |\n|Difos     |D02 |\n|Difos     |D02 |\n+----------+----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["Combined_DataFrame = tree.join(Conditions_1, tree.term == Conditions_1.Conditions).select(tree[\"*\"], Conditions_1[\"*\"])\nCombined_DataFrame.show(20, truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cebd9735-e697-4555-ba2a-b89c7e4d1024"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+------------------------+----+------------------------+\n|term                    |tree|Conditions              |\n+------------------------+----+------------------------+\n|Autistic Disorder       |F03 |Autistic Disorder       |\n|Autism Spectrum Disorder|F03 |Autism Spectrum Disorder|\n|Diabetes Mellitus       |C19 |Diabetes Mellitus       |\n|Diabetes Mellitus       |C18 |Diabetes Mellitus       |\n|Tuberculosis            |C01 |Tuberculosis            |\n|Lung Diseases           |C08 |Lung Diseases           |\n|Diverticular Diseases   |C06 |Diverticular Diseases   |\n|Diverticulum            |C23 |Diverticulum            |\n|Diverticulum            |C06 |Diverticulum            |\n|Diverticulosis          |C23 |Diverticulosis          |\n|Diverticulosis          |C06 |Diverticulosis          |\n|Asthma                  |C20 |Asthma                  |\n|Asthma                  |C08 |Asthma                  |\n|Asthma                  |C08 |Asthma                  |\n|Asthma                  |C08 |Asthma                  |\n|Hypoventilation         |C23 |Hypoventilation         |\n|Hypoventilation         |C08 |Hypoventilation         |\n|Lymphoma                |C20 |Lymphoma                |\n|Lymphoma                |C15 |Lymphoma                |\n|Lymphoma                |C04 |Lymphoma                |\n+------------------------+----+------------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+------------------------+----+------------------------+\n|term                    |tree|Conditions              |\n+------------------------+----+------------------------+\n|Autistic Disorder       |F03 |Autistic Disorder       |\n|Autism Spectrum Disorder|F03 |Autism Spectrum Disorder|\n|Diabetes Mellitus       |C19 |Diabetes Mellitus       |\n|Diabetes Mellitus       |C18 |Diabetes Mellitus       |\n|Tuberculosis            |C01 |Tuberculosis            |\n|Lung Diseases           |C08 |Lung Diseases           |\n|Diverticular Diseases   |C06 |Diverticular Diseases   |\n|Diverticulum            |C23 |Diverticulum            |\n|Diverticulum            |C06 |Diverticulum            |\n|Diverticulosis          |C23 |Diverticulosis          |\n|Diverticulosis          |C06 |Diverticulosis          |\n|Asthma                  |C20 |Asthma                  |\n|Asthma                  |C08 |Asthma                  |\n|Asthma                  |C08 |Asthma                  |\n|Asthma                  |C08 |Asthma                  |\n|Hypoventilation         |C23 |Hypoventilation         |\n|Hypoventilation         |C08 |Hypoventilation         |\n|Lymphoma                |C20 |Lymphoma                |\n|Lymphoma                |C15 |Lymphoma                |\n|Lymphoma                |C04 |Lymphoma                |\n+------------------------+----+------------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["Combined_DataFrame2  = Combined_DataFrame.select(\"tree\").na.drop().groupBy(\"tree\").count().orderBy(\"count\", ascending = False)\nCombined_DataFrame2.show(5, truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"fc801ef2-fd4e-4d29-b152-7380c4d2d245"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----+------+\n|tree|count |\n+----+------+\n|C04 |143994|\n|C23 |136079|\n|C01 |106674|\n|C14 |94523 |\n|C10 |92310 |\n+----+------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----+------+\n|tree|count |\n+----+------+\n|C04 |143994|\n|C23 |136079|\n|C01 |106674|\n|C14 |94523 |\n|C10 |92310 |\n+----+------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 5"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5ca0b186-042c-497b-8014-1c588d623a06"}}},{"cell_type":"code","source":["dbutils.fs.head(\"/FileStore/tables/pharma.csv\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"66ee00a9-420c-4613-9fb2-2a6573cda92b"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"[Truncated to first 65536 bytes]\nOut[54]: '\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon\\'s illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company\\'s industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo\\'s marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage\\'s corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company\\'s drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex\\'s conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company\\'s guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi\\'s acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to'","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["[Truncated to first 65536 bytes]\nOut[54]: '\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon\\'s illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company\\'s industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo\\'s marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage\\'s corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company\\'s drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex\\'s conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company\\'s guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi\\'s acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to'"]}}],"execution_count":0},{"cell_type":"code","source":["Pharma_DataFrame = spark.read.options( delimiter = ',', header= True).csv(\"/FileStore/tables/pharma.csv\")\nPharma_DataFrame.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"a10c9773-f1f8-47f4-ad24-ce7dce20a8ac"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n|             Company|     Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|       Offense_Group|     Primary_Offense|   Secondary_Offense|         Description|Level_of_Government|  Action_Type|              Agency|    Civil/Criminal|Prosecution_Agreement|Court|        Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|    City|             Address|  Zip|NAICS_Code|   NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|         Info_Source|               Notes|\n+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n| Abbott Laboratories|Abbott Laboratories|    $5,475,000|                      $0|                                               $5,475,000|        2013|    20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Abbott Laboratori...|             AbbVie|$1,500,000,000|                      $0|                                           $1,500,000,000|        2012|    20120507|healthcare-relate...|off-label or unap...|                null|Global Health Car...|            federal|agency action|Food and Drug Adm...|civil and criminal|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|http://www.justic...|                null|\n|Abbott Laboratori...|             AbbVie|  $126,500,000|                      $0|                                             $126,500,000|        2010|    20101207|government-contra...|False Claims Act ...|                null|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Abbott Laboratori...|Abbott Laboratories|       $49,045|                      $0|                                                  $49,045|        2009|    20090305|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1527129|                         null|              null|   Puerto Rico|San Juan|                null| null|    423450|423450: Medical, ...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|March 7, 2017 dow...|Date and year are...|\n|      Acclarent Inc.|  Johnson & Johnson|   $18,000,000|                      $0|                                              $18,000,000|        2016|    20160722|government-contra...|False Claims Act ...|                null|California-based ...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Advanced Medical ...|Abbott Laboratories|       $16,800|                      $0|                                                  $16,800|        2004|    20040412|employment-relate...|labor relations v...|                null|back pay award in...|            federal|agency action|National Labor Re...|             civil|                 null| null|21-CA-36104-001|                         null|              null|    California|  Irvine|                null|92606|    333314|333314: Optical I...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|Extracted from an...|                null|\n|Advanced Neuromod...|Abbott Laboratories|    $2,950,000|                      $0|                                               $2,950,000|        2007|    20070702|healthcare-relate...|HHS civil monetar...|kickbacks and bri...|The HHS Inspector...|            federal|agency action|Health & Human Se...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://oig.hhs.g...|                null|\n|Advanced Steriliz...|  Johnson & Johnson|      $136,800|                      $0|                                                 $136,800|        2014|    20140520|environment-relat...|environmental vio...|                null|The U.S. Environm...|            federal|agency action|Environmental Pro...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://archive.e...|                null|\n|Advanced Steriliz...|  Johnson & Johnson|    $1,200,000|                      $0|                                               $1,200,000|        2013|    20131204|safety-related of...|drug or medical e...|                null|Settlement of a c...|            federal|agency action|Food and Drug Adm...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|http://www.fda.go...|                null|\n|Alere San Diego Inc.|Abbott Laboratories|       $10,572|                      $0|                                                  $10,572|        2017|    20170309|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1813371|                         null|              null|    California|  Pomona|828 Towne Center Dr.|91767|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|July 23, 2017 dow...|Date and year are...|\n+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n|             Company|     Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|       Offense_Group|     Primary_Offense|   Secondary_Offense|         Description|Level_of_Government|  Action_Type|              Agency|    Civil/Criminal|Prosecution_Agreement|Court|        Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|    City|             Address|  Zip|NAICS_Code|   NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|         Info_Source|               Notes|\n+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n| Abbott Laboratories|Abbott Laboratories|    $5,475,000|                      $0|                                               $5,475,000|        2013|    20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Abbott Laboratori...|             AbbVie|$1,500,000,000|                      $0|                                           $1,500,000,000|        2012|    20120507|healthcare-relate...|off-label or unap...|                null|Global Health Car...|            federal|agency action|Food and Drug Adm...|civil and criminal|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|http://www.justic...|                null|\n|Abbott Laboratori...|             AbbVie|  $126,500,000|                      $0|                                             $126,500,000|        2010|    20101207|government-contra...|False Claims Act ...|                null|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Abbott Laboratori...|Abbott Laboratories|       $49,045|                      $0|                                                  $49,045|        2009|    20090305|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1527129|                         null|              null|   Puerto Rico|San Juan|                null| null|    423450|423450: Medical, ...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|March 7, 2017 dow...|Date and year are...|\n|      Acclarent Inc.|  Johnson & Johnson|   $18,000,000|                      $0|                                              $18,000,000|        2016|    20160722|government-contra...|False Claims Act ...|                null|California-based ...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Advanced Medical ...|Abbott Laboratories|       $16,800|                      $0|                                                  $16,800|        2004|    20040412|employment-relate...|labor relations v...|                null|back pay award in...|            federal|agency action|National Labor Re...|             civil|                 null| null|21-CA-36104-001|                         null|              null|    California|  Irvine|                null|92606|    333314|333314: Optical I...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|Extracted from an...|                null|\n|Advanced Neuromod...|Abbott Laboratories|    $2,950,000|                      $0|                                               $2,950,000|        2007|    20070702|healthcare-relate...|HHS civil monetar...|kickbacks and bri...|The HHS Inspector...|            federal|agency action|Health & Human Se...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://oig.hhs.g...|                null|\n|Advanced Steriliz...|  Johnson & Johnson|      $136,800|                      $0|                                                 $136,800|        2014|    20140520|environment-relat...|environmental vio...|                null|The U.S. Environm...|            federal|agency action|Environmental Pro...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://archive.e...|                null|\n|Advanced Steriliz...|  Johnson & Johnson|    $1,200,000|                      $0|                                               $1,200,000|        2013|    20131204|safety-related of...|drug or medical e...|                null|Settlement of a c...|            federal|agency action|Food and Drug Adm...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|http://www.fda.go...|                null|\n|Alere San Diego Inc.|Abbott Laboratories|       $10,572|                      $0|                                                  $10,572|        2017|    20170309|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1813371|                         null|              null|    California|  Pomona|828 Towne Center Dr.|91767|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|July 23, 2017 dow...|Date and year are...|\n+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["ClinicalPharma= clinical_DF.join(Pharma_DataFrame, clinical_DF.Sponsor == Pharma_DataFrame.Parent_Company, \"left\")\nClinicalPharma.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"53d9f933-ba3a-4e37-9172-aaf8bd242065"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+-------+--------------+--------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+-----------------+-----------+-------------------+-----------+------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+-----------+-----+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|Company|Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group|Primary_Offense|Secondary_Offense|Description|Level_of_Government|Action_Type|Agency|Civil/Criminal|Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City|Address| Zip|NAICS_Code|NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source|Notes|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+-------+--------------+--------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+-----------------+-----------+-------------------+-----------+------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+-----------+-----+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+-------+--------------+--------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+-----------------+-----------+-------------------+-----------+------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+-----------+-----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+-------+--------------+--------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+-----------------+-----------+-------------------+-----------+------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+-----------+-----+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|Company|Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group|Primary_Offense|Secondary_Offense|Description|Level_of_Government|Action_Type|Agency|Civil/Criminal|Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City|Address| Zip|NAICS_Code|NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source|Notes|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+-------+--------------+--------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+-----------------+-----------+-------------------+-----------+------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+-----------+-----+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|   null|          null|          null|                    null|                                                     null|        null|        null|         null|           null|             null|       null|               null|       null|  null|          null|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                null|              null|               null|                       null|                    null|                       null|       null| null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+-------+--------------+--------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+-----------------+-----------+-------------------+-----------+------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+-----------+-----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["ClinicalPharma2 = ClinicalPharma.select(\"Sponsor\" , \"Parent_Company\").where(\"Parent_Company is null\").groupBy([\"Sponsor\"]).count().orderBy(\"count\", ascending =False)\nClinicalPharma2.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f7976fae-fc08-4d67-a459-d522a106e83a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3218|\n|M.D. Anderson Can...| 2414|\n|Assistance Publiq...| 2369|\n|         Mayo Clinic| 2300|\n|Merck Sharp & Doh...| 2243|\n|   Assiut University| 2154|\n|Novartis Pharmace...| 2088|\n|Massachusetts Gen...| 1971|\n|    Cairo University| 1928|\n|   Hoffmann-La Roche| 1828|\n+--------------------+-----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3218|\n|M.D. Anderson Can...| 2414|\n|Assistance Publiq...| 2369|\n|         Mayo Clinic| 2300|\n|Merck Sharp & Doh...| 2243|\n|   Assiut University| 2154|\n|Novartis Pharmace...| 2088|\n|Massachusetts Gen...| 1971|\n|    Cairo University| 1928|\n|   Hoffmann-La Roche| 1828|\n+--------------------+-----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["QUESTION 6"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c95a5960-ca48-4b16-b6cb-1b51a68e7c01"}}},{"cell_type":"code","source":["Completed_Studies = clinical_DF.filter(\"Status == 'Completed'\")\nCompleted_Studies.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8ef2cd07-4017-4e6a-b87c-ce9144014a1c"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|   Status|   Start|Completion|          Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+--------------------+\n|NCT02751957|     Duke University|Completed|Jul 2016|  Jul 2020|Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|Completed|Mar 2017|  Jan 2018|Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|Completed|Jan 2012|  Dec 2014| Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02757209|Consorzio Futuro ...|Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02757508|Washington Univer...|Completed|Mar 2016|  Jul 2017|Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|Completed|Aug 2017|  Jan 2021|Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|Completed|Apr 2016|  Oct 2016| Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|Completed|May 2015|  Dec 2015| Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|Completed|Jun 2015|  Mar 2016| Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+--------------------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|   Status|   Start|Completion|          Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+--------------------+\n|NCT02751957|     Duke University|Completed|Jul 2016|  Jul 2020|Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|Completed|Mar 2017|  Jan 2018|Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|Completed|Jan 2012|  Dec 2014| Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02757209|Consorzio Futuro ...|Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02757508|Washington Univer...|Completed|Mar 2016|  Jul 2017|Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|Completed|Aug 2017|  Jan 2021|Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|Completed|Apr 2016|  Oct 2016| Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|Completed|May 2015|  Dec 2015| Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|Completed|Jun 2015|  Mar 2016| Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n+-----------+--------------------+---------+--------+----------+--------------+----------+--------------------+--------------------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["CompletedMonth = clinical_DF.filter(clinical_DF.Status == 'Completed').filter(clinical_DF.Completion.endswith('2021')).groupBy('Completion').count().withColumn('Completion', split(col('Completion'), ' ').getItem(0)).sort('Completion', inplace = True)\nCompletedMonth.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"679e6d18-2ebe-46cf-9b8e-ceb6aaeb1d91"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[59]: [Row(Completion='Apr', count=967),\n Row(Completion='Aug', count=700),\n Row(Completion='Feb', count=934),\n Row(Completion='Jan', count=1131),\n Row(Completion='Jul', count=819),\n Row(Completion='Jun', count=1094),\n Row(Completion='Mar', count=1227),\n Row(Completion='May', count=984),\n Row(Completion='Oct', count=187),\n Row(Completion='Sep', count=528)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[59]: [Row(Completion='Apr', count=967),\n Row(Completion='Aug', count=700),\n Row(Completion='Feb', count=934),\n Row(Completion='Jan', count=1131),\n Row(Completion='Jul', count=819),\n Row(Completion='Jun', count=1094),\n Row(Completion='Mar', count=1227),\n Row(Completion='May', count=984),\n Row(Completion='Oct', count=187),\n Row(Completion='Sep', count=528)]"]}}],"execution_count":0},{"cell_type":"code","source":["from pyspark.sql.functions import unix_timestamp\nMonths_Completed_Studies = CompletedMonth.sort(unix_timestamp(col('Completion'), 'MMM'))\nMonths_Completed_Studies2.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"9feeb9c8-bdd8-4c03-8b0e-28bd93435553"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------+-----+\n|Completion|count|\n+----------+-----+\n|       Jan| 1131|\n|       Feb|  934|\n|       Mar| 1227|\n|       Apr|  967|\n|       May|  984|\n|       Jun| 1094|\n|       Jul|  819|\n|       Aug|  700|\n|       Sep|  528|\n|       Oct|  187|\n+----------+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------+-----+\n|Completion|count|\n+----------+-----+\n|       Jan| 1131|\n|       Feb|  934|\n|       Mar| 1227|\n|       Apr|  967|\n|       May|  984|\n|       Jun| 1094|\n|       Jul|  819|\n|       Aug|  700|\n|       Sep|  528|\n|       Oct|  187|\n+----------+-----+\n\n"]}}],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"COURSEWORK in DF","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":2537901111588437}},"nbformat":4,"nbformat_minor":0}
